Everolimus for Liver Cancer

This trial aims to determine if using Everolimus, an immunosuppressant, after a liver transplant can prevent the recurrence of liver cancer and improve survival rates. Participants will receive either Everolimus with Tacrolimus or Tacrolimus with another medication, and researchers will compare the effectiveness of each combination. Individuals who have had a liver transplant due to liver cancer and are at high risk of recurrence might be suitable for this trial. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, and this research seeks to understand its benefits for more patients.

The trial information does not specify if you need to stop taking your current medications. However, if you are taking sirolimus (Rapamune), you cannot participate in the study.

Studies have shown that Everolimus, when used with Tacrolimus, aids liver transplants. Everolimus blocks certain proteins that enable cancer cell growth. This treatment primarily reduces the risk of cancer recurrence after liver transplants.

Reported side effects include infections and kidney problems, common in transplant patients due to medications that prevent organ rejection. Everolimus has approval for other conditions, indicating its safety has been studied in humans.

Tacrolimus, another medicine in this trial, prevents the immune system from attacking the new liver. It is generally well-tolerated but can cause side effects like high blood pressure and diabetes.

Everolimus is unique because it offers a novel approach to managing liver transplant patients with liver cancer by targeting a different pathway. Most standard treatments, like Tacrolimus combined with Myfortic, CellCept, or Imuran, primarily focus on suppressing the immune response to prevent organ rejection. Everolimus, on the other hand, also inhibits a protein called mTOR, which plays a crucial role in cancer cell growth and proliferation. This dual action not only helps prevent rejection but also directly combats cancer cells, potentially improving outcomes for patients. Researchers are excited about this treatment's potential to enhance both transplant success and cancer control.

Research has shown that using Everolimus with Tacrolimus, one of the treatment combinations in this trial, can help prevent liver tumors from returning after a liver transplant for liver cancer. Studies have found that patients taking Everolimus and a low dose of Tacrolimus experienced better kidney function, which is crucial after a transplant. Everolimus has also been used successfully in other organ transplants, yielding good long-term results. This combination aims to maintain the health of the transplanted liver while reducing the chance of cancer recurrence. Overall, using Everolimus with Tacrolimus offers a promising approach to improving outcomes for liver cancer patients post-transplant.⁶⁷⁸⁹¹⁰